Renhuang Pharmaceuticals, Inc. (“Renhuang” or the “Company”, stock symbol: RHGP.OB), a leading Chinese integrated drug developer, manufacturer and distributor, announced the successful laboratory production of lyophilized syringin powder, its new powder injection anti-depression and fatigue drug. Renhuang expects this new drug to become its next revenue growth driver. At 90% purity, the syringin portion in the sample drugs meets the criteria of the State Food and Drug Administration (SFDA).
Popularity: unranked [?]
Related posts:
- Renhuang Pharmaceuticals Announces Breakthrough In Study Of New Form Of Anti-Depression Chinese Medicine: Lyophilized Syringin Powder For Injection
- Auspex Pharmaceuticals Announces Positive Results From Clinical Study Of SD-254, A Next-Generation Potential Treatment For Depression
- Auspex Pharmaceuticals Announces Positive Results From Clinical Study Of SD-254, A Next-Generation Potential Treatment For Depression
- FDA Adds Strong Warnings To Anti-Smoking Drug Labels
- St. Jude Medical Announces Clinical Study Of Deep Brain Stimulation For Depression
Comments
No Responses to “Renhuang Pharmaceuticals Announces Breakthrough In Study Of New Form Of Anti-Depression Chinese Medicine: Lyophilized Syringin Powder For Injection”